Silodosin

證據等級: L5

預測適應症: 6 個

Silodosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Silodosin is a highly selective alpha-1A adrenergic receptor antagonist originally used to relieve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita with a 99.99% score, but this and all five other top-ranked predictions are supported by zero clinical trials and no relevant literature — the evidence pack itself flags them as likely embedding-space artifacts with no plausible biological mechanism.

Quick Overview

Item	Content
Original Indication	Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) — not present in this evidence pack; TFDA package insert data is flagged as a blocking gap (DG001)
Predicted New Indication	Ambras type hypertrichosis universalis congenita (congenital generalized hypertrichosis)
TxGNN Prediction Score	99.99% (rank 153 among all disease candidates)
Evidence Level	L5 (model prediction only, no supporting studies)
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation is not available in this evidence pack (flagged as data gap DG002), but based on publicly available drug reference data, silodosin is a highly α1A-selective adrenergic receptor antagonist that relaxes smooth muscle in the prostate and urethra, relieving BPH-related voiding symptoms. Its selectivity for α1A over α1B receptors is what limits cardiovascular side effects relative to older, non-selective alpha blockers.

There is no known or biologically plausible mechanistic pathway connecting α1A-adrenergic antagonism to Ambras syndrome, which is a congenital disorder linked to chromosomal rearrangements near 8q affecting TRPS1 gene regulation and hair follicle development — an entirely distinct biological system from smooth-muscle adrenergic signaling.

The evidence pack's own repurposing rationale is explicit on this point: the TxGNN score of 0.9999 is assessed as a likely spurious correlation within the model's knowledge-graph embedding space, with no supporting biological hypothesis. The same pattern repeats across all six top-ranked predictions in this pack (hypertrichosis, a periodontal malformation syndrome, Dandy-Walker malformation, a hair-shaft structural disorder, and familial trichomegaly) — none has a credible mechanistic link to α1A antagonism, and the periodontal-disease literature that did surface (20 PubMed hits) was confirmed to be keyword-matching noise unrelated to silodosin.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Silodosin is not currently marketed in Finland (0 authorizations on record), so no product license information is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has no clinical trials, no relevant literature, and no biologically plausible mechanistic link to silodosin's known α1A-adrenergic antagonism — the evidence pack itself characterizes the TxGNN score as a likely spurious embedding-space correlation. All five other top-ranked predictions in this pack show the identical pattern (L5 evidence, Hold recommendation), reinforcing that this candidate set is not ready for further evaluation.

To proceed, the following is needed:

TFDA/official package insert with warnings, contraindications, and confirmed original indication text (blocking gap, DG001)
Verified mechanism-of-action data from DrugBank or equivalent primary source (DG002)
A biologically grounded hypothesis (e.g., from dermatology/endocrinology literature) before any further investment in the hypertrichosis-related predictions
Re-screening once TxGNN model version or training data is updated, given the current rank (153) is far outside typical high-confidence repurposing candidates

Sources:

[Silodosin: Uses, Interactions, Mechanism of Action DrugBank](https://go.drugbank.com/drugs/DB06207)
Silodosin - Wikipedia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.